Association of RNA m7G Modification Gene Polymorphisms with Pediatric Glioma Risk
Table 2
Stratification analysis between METTL1 genotypes and glioma risk.
Variables
rs2291617 (cases/controls)
AOR (95% CI)a
a
rs10877012 (cases/controls)
AOR (95% CI)a
a
Risk genotypesb (cases/controls)
AOR (95% CI)a
a
GG/GT
TT
TT/TG
GG
0
1–3
Age, month
<60
109/153
24/21
1.60 (0.85-3.03)
0.145
111/155
22/19
1.61 (0.83-3.12)
0.156
109/153
24/21
1.60 (0.85-3.03)
0.145
≥60
147/177
32/29
1.32 (0.76-2.28)
0.323
146/177
33/29
1.37 (0.80-2.37)
0.256
145/177
34/29
1.42 (0.83-2.44)
0.205
Gender
Females
119/140
26/24
1.23 (0.67-2.26)
0.513
119/141
26/23
1.29 (0.70-2.39)
0.420
118/140
27/24
1.29 (0.70-2.36)
0.417
Males
137/190
30/26
1.61 (0.91-2.85)
0.102
138/191
29/25
1.60 (0.90-2.85)
0.113
136/190
31/26
1.67 (0.95-2.94)
0.076
Subtypes
Astrocytic tumors
173/330
39/50
1.47 (0.93-2.35)
0.101
173/332
39/48
1.53 (0.96-2.44)
0.076
171/330
41/50
1.56 (0.99-2.47)
0.057
Ependymoma
51/330
10/50
1.42 (0.66-3.03)
0.366
52/332
9/48
1.35 (0.61-2.96)
0.461
51/330
10/50
1.42 (0.66-3.03)
0.366
Neuronal and mixed
20/330
5/50
1.68 (0.60-4.70)
0.325
20/332
5/48
1.75 (0.62-4.92)
0.287
20/330
5/50
1.68 (0.60-4.70)
0.325
Embryonal tumors
10/330
2/50
0.93 (0.19-4.71)
0.934
10/332
2/48
0.95 (0.19-4.83)
0.954
10/330
2/50
0.93 (0.19-4.71)
0.934
Clinical stages
183/330
41/50
1.46 (0.93-2.29)
0.103
186/332
38/48
1.39 (0.87-2.20)
0.169
183/330
41/50
1.46 (0.93-2.29)
0.103
72/330
15/50
1.32 (0.70-2.50)
0.388
70/332
17/48
1.61 (0.87-2.97)
0.131
70/330
17/50
1.54 (0.83-2.84)
0.168
AOR: adjusted odds ratio; CI: confidence interval. aAdjusted for age and gender, omitting the corresponding stratify factor. bRisk genotypes were carriers with rs2291617 TT, rs10877013 CC, and rs10877012 GG genotypes.
